This site is intended for US health care professionals only.

IMPORTANT SAFETY INFORMATION

This site is intended for US healthcare professionals only.

WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Vyvanse is indicated for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

Titrate to the Target Dose of 50 to 70 mg/day¹

The Recommended Starting Dose is 30 mg/day¹

Titrate in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 to 70 mg/day (70 mg/day=max dose). Discontinue Vyvanse if binge eating does not improve.

Take once daily in the morning, with or without food

  • Avoid afternoon doses because of the potential for insomnia

SAFETY INFORMATION

  • Severe renal impairment: Maximum dose should not exceed 50 mg/day; end-stage renal disease (ESRD): Maximum recommended dose is 30 mg/day.
  • Prior to treatment, assess for cardiac disease and risk for abuse; after prescribing, keep prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and re-evaluate the need for Vyvanse use.

Dose Distribution During the 8-week Dose Maintenance Period of Study 1*2,3

*Patients were optimized to 50 or 70 mg during a 4-week dose optimization period.
The doses remained fixed during the 8-week dose maintenance period.¹


Similar dose distributions were seen in the second, identically designed trial.2,3

Shire

All content of this Web site including text, images, graphics, sound files, and their arrangements, belongs to Shire and is protected by international copyrights laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our online privacy policy for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

S38425  04/18

You are about to leave vyvansepro.com.

Please be advised that Shire has no control over the content or presentation of the site you are about to view.

Cancel Continue